https://www.pharmaceutical-technology.com/analyst-comment/escmid-global-2026-adibelivir-emerges-as-potential-disease-modifying-therapy-for-hsv/
ESCMID Global 2026: Adibelivir emerges as potential disease-modifying therapy for HSV -...
Apr 23, 2026 - Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical trials.
escmid global 2026disease modifying therapy